(0.77%) 5 473.23 points
(0.49%) 38 778 points
(0.95%) 17 857 points
(-0.19%) $80.18
(0.57%) $2.80
(0.45%) $2 339.50
(0.66%) $29.59
(0.88%) $979.40
(0.11%) $0.933
(0.23%) $10.68
(0.07%) $0.788
(0.32%) $88.73
Live Chart Being Loaded With Signals
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells...
Stats | |
---|---|
今日成交量 | 94 426 |
平均成交量 | 262 332 |
市值 | 9.57M |
EPS | $-0.240 ( Q2 | 2023-08-10 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.225 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0390 (10.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-23 | Zabrowksi Dan | Sell | 100 000 | Stock Option (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 146 383 | Common Stock |
2023-08-23 | Wertheimer Samuel P | Sell | 100 000 | Stock Option (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 12 383 | Warrants (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 1 845 | Warrants (right to buy) |
INSIDER POWER |
---|
-62.55 |
Last 97 transactions |
Buy: 2 466 920 | Sell: 6 182 886 |
音量 相关性
Apexigen, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Apexigen, Inc. 相关性 - 货币/商品
Apexigen, Inc. 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.590 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.590 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.931 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.36 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Apexigen, Inc.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。